BI-9627 |
BI-9627 : Antagonist of SLC9A1
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| SLC9A1 |
|
|
Antagonist
up to 5 uM
Selectivity
In Vitro Selectivity Assessment
Selectivity Assessment Description:
Solute carrier family 9 isoform selectivity: > 30-fold selective versus SLC9A2 (IC50 = 231 nM) and > ...
Potency Cellular
In Vitro
SLC9A1
Mode of Action: Antagonist
Structure-Activity-Relationship data available? No
DOI Reference: 10.1021/jm300601d
In Vivo Validations
Rat
Dose: 1 mg/Kg IV, 5 mg/Kg PO
Route of delivery:
Intravenous, Oral
Systemic clearance:
5.7 %QH
Tmax:
3.2 h
Bioavailability:
73%
Volume of Distribution at Steady-State:
0.76 L/kg
Target engagement assay:
Efficacious in a rat model of coronary artery ligation at 150 ppm in chow.
DOI Reference: 10.1021/jm300601d
Dose:
Target engagement assay:
Efficacious in a rat model of coronary artery ligation at 150 ppm in chow.
DOI Reference: 10.1124/jpet.114.217091
Dog
Dose: 1 mg/Kg IV, 5 mg/Kg PO
Route of delivery:
Intravenous, Oral
Systemic clearance:
13 %QH
Tmax:
6.2 h
Bioavailability:
33%
Volume of Distribution at Steady-State:
1.4 L/Kg
DOI Reference: 10.1021/jm300601d
Negative Control Compounds
BI 0054
Notes: pHi change assay: SLC9A1 IC50 > 10 µM; SLC9A2 and SLC9A3 IC50 > 10 µM; hPSA assay: IC50 > 10 µM; Clean GPCR scan with the closest hit on SLC6A3 (pKi = 6.1)
Chemical Information
| Molecular Formula | C16H19F3N4O2 |
| SMILEs | CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1 |
| InChI | InChI=1S/C16H19F3N4O2/c1-9(24)23-6-4-10(5-7-23)12-3-2-11(14(25)22-15(20)21)8-13(12)16(17,18)19/h2-3,8,10H,4-7H2,1H3,(H4,20,21,22,25) |
| Molecular weight | 356.15 Da |
| AlogP | 2.05457 |
| HBond acceptors | 6 |
| HBond donors | 4 |
| Atoms | 44 |
References
Publications
Vendors
Note: This is not an exhaustive list and does not indicate endorsement by the portal.